Effect of ultra-low dose of dicitabine on myelodysplastic syndrome
Objective To observe the clinical efficacy and safety of ultra-low dose of dexamethabine in the treatment of myelodysplastic syndrome(MDS).Methods A total of 46 patients with MDS who were admitted to the Affiliated Cancer Hospital of Zhengzhou University from January 2015 to January 2019 and treated with ultra-low dose decitabine regimen were selected as the study objects.All patients were treated with an ultra-low dose of decitabine and an increased frequency of administration.The clinical curative effect and adverse reactions were observed.Results Among the 46 MDS patients,9 cases had complete response(CR),18 cases had bone marrow response with incomplete hemologic recovery(CRi)+hematologic progress(HI),4 cases had HI,10 cases had no disease progression(SD),and 5 cases had disease progression(PD).The CR was 19.6％,the HI was 47.8％,and the total response rate(ORR,CR and CRi+HI and HI)was 67.4％.All patients had transient myelosuppression during treatment,of which 2 patients had moderate myelosuppression during induction therapy,and no grade 3 to 4 treatment-related adverse reactions were observed.Conclusions The treatment of myelodysplastic syndrome with ultra-low dose of decitabine is safe and effective by increasing the frequency of administration.
NETL
NSTL
万方数据
